Published in Gene Therapy Weekly, June 24th, 2004
The privately held biotech company manufactures DNA vectors, complex molecules used by the global life sciences industry to reprogram the biological activity of cells. Genomatix specializes in producing combinatorial sets of DNA vectors that can be used for comparative transgenic studies in cell lines and organisms.
According to Thomas D. Reed, Ph.D., Genomatix chairman and chief science officer, the company has spent almost two years considering...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly